Cerus Corporation 2017 Q1 Form 10-Q Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction of platelets and plasma. The platelet and plasma systems were FDA-approved in December 2014 and are marketed in the United States and selected international markets. The red blood cell system remains in development. This unaudited Form 10-Q covers the three months ended March 31, 2017, with comparison to the three months ended March 31, 2016.
Key financial metrics
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Total revenue | $8.434 million | $7.632 million | Up 11% |
| Product revenue | $7.006 million | $7.632 million | Down 8% |
| Government contracts revenue | $1.428 million | — | New BARDA revenue |
| Gross profit on product revenue | $3.312 million | $3.369 million | Down 2% |
| Product gross margin | 47% | 44% | Up approximately 3 points |
| Research and development expense | $9.150 million | $6.917 million | Up 32% |
| SG&A expense | $13.633 million | $11.747 million | Up 16% |
| Loss from operations | $(18.093) million | $(15.345) million | Loss increased |
| Net loss | $(18.598) million | $(16.863) million | Loss increased 10% |
| Net loss per share | $(0.18) | $(0.17) | — |
| Cash used in operating activities | $(16.348) million | $(13.043) million | Use increased |
Total revenue increased because $1.4 million of BARDA reimbursement revenue more than offset the $0.6 million decline in product revenue. Product revenue was affected primarily by weaker European and Middle Eastern plasma demand and approximately 3% unfavorable euro translation, partly offset by U.S. disposable-kit growth.
Product gross margin improved to approximately 47% from 44%, driven by product mix and manufacturing and inventory-management efficiencies. Despite the higher product margin and BARDA revenue, increased R&D and commercial expenses produced a larger operating and net loss. Stock-based compensation expense was $2.147 million, compared with $1.776 million in the prior-year quarter.
Liquidity, cash flow, debt, and balance sheet
- Cash and cash equivalents were $10.930 million at March 31, 2017, compared with $22.560 million at December 31, 2016.
- Short-term investments were $39.117 million and marketable equity securities were $3.710 million. Total cash, cash equivalents, and investments were approximately $53.8 million, excluding restricted cash.
- Working capital declined to $49.3 million from $67.2 million at year-end 2016.
- Total debt was approximately $18.2 million, consisting of $7.7 million current debt and $10.5 million non-current debt. The Oxford term loans bear interest rates of 6.95% and 7.01% and mature June 1, 2019.
- Net cash used in operating activities was $16.3 million. Investing activities provided $5.7 million, principally from net investment maturities and sales. Financing activities used $0.9 million, including $1.3 million of debt repayment.
- At March 31, 2017, the company had $62.3 million available under its at-the-market equity sales agreement, although no shares were sold under the agreement during the quarter.
- Management stated that available cash, investments, expected product receipts, and BARDA funding were expected to satisfy capital requirements for at least the following twelve months, subject to significant assumptions regarding revenue, funding access, and spending.
Material changes versus the prior comparable period
- Total revenue rose 11%, but underlying product revenue declined 8%; the increase depended on newly recognized BARDA revenue.
- R&D spending increased 32%, primarily for red blood cell clinical development, platelet and plasma supplement approvals, and BARDA activities.
- SG&A increased 16% due primarily to U.S. commercialization and BARDA administration.
- Operating loss increased from $15.3 million to $18.1 million, and net loss increased from $16.9 million to $18.6 million.
- Operating cash burn increased by $3.3 million year over year.
- The company began repaying principal on its Oxford loan in January 2017, reducing debt by approximately $1.2 million during the quarter.
- In April 2017, after the reporting date, the Oxford loan was amended to provide interest-only payments from May through December 2017, followed by eighteen months of equal principal and interest payments.
Guidance, outlook, commentary, risks, and unusual items
Management expected product revenue to increase over time as INTERCEPT gains market acceptance, including through U.S. commercialization and newly accessible geographies. Management also expected higher R&D and SG&A spending as clinical programs, BARDA activities, post-approval studies, regulatory work, and U.S. commercial capabilities expand. The filing does not provide formal quantitative full-year revenue or earnings guidance.
- The BARDA agreement provides committed funding of up to $41.6 million for the base period and exercised options, with a potential total opportunity of up to $186.2 million over five years. Additional funding depends on BARDA exercising options and the company meeting milestones; BARDA may terminate for convenience.
- The company remains dependent on continued product adoption, particularly in the U.S., where customer implementation, site-specific licensing, reimbursement, and blood-center economics may delay revenue growth.
- The red blood cell system requires additional clinical, regulatory, and development work. The company stated that it did not expect regulatory approval within the next twelve months, if ever.
- Fresenius is the principal and sole supplier for certain finished disposable kits. Other components also rely on sole or limited qualified suppliers, creating manufacturing, quality, obsolescence, and supply-continuity risks.
- The company had $9.5 million of minimum purchase commitments, a remaining Fresenius manufacturing and development payment obligation of $5.9 million, and $2.5 million of future operating lease payments as of March 31, 2017.
- Government-contract revenue is subject to future audits, which could result in potentially significant adjustments. Accounts receivable also remained concentrated among three customers representing approximately 39% of outstanding trade receivables.
- The company held 345,100 Aduro shares valued at $3.7 million at quarter-end and recorded a $0.02 million realized gain from selling 1,600 shares. Unrealized investment losses of $0.2 million were recorded in other comprehensive loss.
- No legal proceedings were reported, and management concluded that disclosure controls were effective as of March 31, 2017.
Most important facts for investors to verify
- Whether U.S. adoption of the platelet and plasma systems produces sustained product-revenue growth sufficient to reduce cash burn.
- The timing, amount, and conditions of future BARDA option exercises and reimbursements.
- Progress, cost, enrollment, and regulatory outcomes for the red blood cell program and required post-approval studies.
- Remaining cash runway after considering quarterly operating cash use, debt repayments, manufacturing commitments, and planned commercialization spending.
- Fresenius and other supplier capacity, qualification, product-obsolescence, and regulatory-compliance status.
- Potential need for additional equity or debt financing and the resulting dilution, covenants, or collateral risks.
- Whether product gross-margin improvement is sustainable amid foreign-exchange movements, product mix, pricing pressure, and manufacturing costs.